Invivyd announces VYD222 shows neutralizing activity against KP.1.1 and KP.3 SARS-CoV-2 variants

Invivyd, Inc.

VYD222 demonstrated in vitro neutralization of KP.1.1 FLiRT and KP.3 variants in pseudovirus assays.
Epitope at VYD222 binding interface is 99.8% conserved among 2024 GISAID sequences.
Next candidate VYD2311 also shows continued in vitro neutralization against these dominant strains.
FLiRT variants account for >50% of circulating SARS-CoV-2 sequences as of June 8, 2024.
CDC predicts KP.3 will become the most dominant lineage nationally in the near term.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.